Lung cancer outcomes at a UK cancer unit between 1998-2001
Lung cancer outcomes at a UK cancer unit between 1998-2001
复制标题
DOI：
10.1016/j.lungcan.2007.03.006
复制
发表时间：
2007-08-01
期刊：
影响因子：
5.3
通讯作者：
Baldwin, D. R.
中科院分区：
文献类型：
--
作者：
Free, C. M.;Ellis, M.;Baldwin, D. R.
在英国，关于肺癌生存率的数据很少。生存率为肺癌在英国医院之间1998- 2001described.Methods：从多学科小组（MDT）会议，肺癌登记和医院编码收集的数据进行分析。诊断出835例新肺癌，包括597例非小细胞肺癌（NSCLC）（71%），133例小细胞肺癌（SCLC）（16%），临床诊断105例（13%）。诊断时分期：I期（25%）、II期（9%）、IIIA期（8%）、IIIB期（23%）、IV期（35%）。12%的患者接受了手术治疗，4%接受了根治性放疗（RT），32%接受了姑息性RT，8%接受了化疗，36%接受了最佳支持治疗（BSC）。NSCLC的3年累积生存率为：I期39%，II期30%，III期6%，IV期0.5%。只有46%的I-IIIA期患者接受了根治性治疗。原因包括肺功能差（32%），不可切除（24%），合并症（17%），性能状态（8%），患者的选择（8%），不清楚（6%），高龄（5%）。结论：生存数字是类似于其他英国的研究，但并不优于美国和欧洲的数据。这可能是因为大部分早期疾病患者仅接受姑息治疗。(C)2007爱思唯尔爱尔兰有限公司保留所有权利。
There are few data published on lung cancer survival in the UK. Survival rates for lung cancer at a UK Hospital between 1998-2001 are described.Methods: Analysis of data collected from multidisciplinary team (MDT) meetings, lung cancer registrations and hospital coding.Results: 835 new lung cancers were diagnosed comprising 597 non-small cell lung cancers (NSCLC) (71%), 133 small cell (SCLC) (16%), and 105 clinical diagnoses (13%). Stage at diagnosis; stage I (25%), II (9%), IIIA (8%), IIIB (23%), IV (35%). Surgery was undertaken in 12%, radical radiotherapy (RT) in 4%, palliative RT in 32%, chemotherapy in 8% and best supportive care (BSC) in 36%. The 3-year cumulative survival for NSCLC was: stage I 39%, stage II 30%, stage III 6%, stage IV 0.5%. Only 46% of patients with stage I-IIIA disease received radical treatment. Reasons included poor lung function (32%), unresectable (24%), co-morbidities (17%), performance status (8%), patient choice (8%), unclear (6%), advanced age (5%).Conclusions: Survival figures are similar to other UK studies but do not compare favourably with US and European data. This may be because a large proportion of patients with early stage disease receive palliative care only. (C) 2007 Elsevier Ireland Ltd. All rights reserved.